Skip to main content
Quest Diagnostics

A Retrospective Review of Postmortem Genetic Testing Result From a Comprehensive Cardiomyopathy and Arrhythmia Next-Generation Sequencing Panel

ICCG 2024

International Clinical Cardiovascular Genetics Conference

Brisbane, Australia, May 8-10, 2024

Poster presentation: A Retrospective Review of Postmortem Genetic Testing Result From a Comprehensive Cardiomyopathy and Arrhythmia Next-Generation Sequencing Panel

Authors: Zilliacus E, Hathaway J, Huusko J, Cicerchia M, Ahonen S, Tommiska J, Gall K, Sluyters A, Lewis A, Liaquat K, Partack E, Howell V, Dodge W, Djupsjöbacka J, Muona M, Saarinen I, Seppälä E, Kangas-Kontio T, Koskinen L, Salmenperä P, Myllykangas S, Koskenvuo J

Specialty: Genetics, Cardiology, Endocrinology

Disclaimer: One or more of the authors of this abstract were employed at the time by BluePrint Genetics, a subsidiary of Quest Diagnostics.

Related content

Conference Presentation
Genetic Findings for Cardiomyopathy and Arrhythmia: A Retroactive Analysis of Over 1,800 Patients
Publication
Novel filamin C FLNC variant causes a severe form of familial mixed hypertrophic restrictive cardiomyopathy
Publication
Recessive TMOD1 mutation causes childhood cardiomyopathy

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.